Anthem Biosciences
MAINBOARD
Listed
Price Band
₹540 - ₹570
Lot Size
26 Shares
Issue Size
₹3,395.00 Cr
Fresh Issue
₹2,376.50 Cr
OFS
₹1,018.50 Cr
Registrar
KFin Technologies Limited
AI Sentiment Score
Listing Price
₹723.00
vs Issue: ₹570 (+26.84%)
📅 IPO Timeline
✓
Open
Jul 14, 2025
✓
Close
Jul 16, 2025
✓
Allotment
Jul 17, 2025
✓
Refund
Jul 18, 2025
✓
Demat
Jul 18, 2025
✓
Listing
Jul 21, 2025
📈 Grey Market Premium (GMP) Trendline
Daily consensus GMP movement (₹) recorded across market sources
✨ AI Analysis & Prediction
🔒 Final Reconciled Estimate
Locked post-listing with actual debut performance
Anthem Biosciences displays an established operational footprint with expanding revenue streams (26.2% CAGR) and a defensible value proposition.
💪 Strengths
- Demonstrated operational revenue trajectory with resilient top-line growth (26.2% CAGR).
- Established customer relationships and market position across target industry sectors.
- Sound operational capital returns with Return on Capital Employed (ROCE) at 30.4%.
⚠️ Weaknesses
- Exposure to input cost fluctuations and broader macroeconomic supply chain cycles.
- Working capital requirements to support continuous capacity expansion.
- Competitive landscape from both established incumbents and specialized regional players.
🚀 Opportunities
- Industry tailwinds from rising domestic capex and infrastructure spending.
- Operating leverage potential allowing margin expansion as manufacturing utilization rises.
- Geographic diversification and entry into higher-margin specialized product lines.
🛡️ Threats
- Sectoral regulatory shifts and evolving statutory compliance requirements.
- Aggressive pricing actions by domestic competitors impacting gross margins.
- Broader market equity volatility and liquidity fluctuations.
📊 Financial Overview & Growth Trajectory
Multi-year operational scale & net profitability trajectory
| Metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue (₹ Cr) | Rs 1,057.00 Cr | Rs 1,419.00 Cr | Rs 1,845.00 Cr | Rs 2,124.00 Cr |
| Net Profit / PAT (₹ Cr) | Rs 385.00 Cr | Rs 367.00 Cr | Rs 451.00 Cr | Rs 592.00 Cr |
| EBITDA / Op. Profit (₹ Cr) | Rs 431.00 Cr | Rs 506.00 Cr | Rs 672.00 Cr | Rs 834.00 Cr |
| Borrowings (₹ Cr) | Rs 126.00 Cr | Rs 239.00 Cr | Rs 113.00 Cr | Rs 54.00 Cr |
| Total Assets (₹ Cr) | Rs 2,014.00 Cr | Rs 2,398.00 Cr | Rs 2,808.00 Cr | Rs 3,429.00 Cr |
| ROE % | 0.00% | 0.00% | 0.00% | 0.00% |
| ROCE % | 30.40% | 30.40% | 30.40% | 30.40% |
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 |
Company P/E
84.5x
Industry P/E
97.2x
Debt/Equity
0.02
⚖️ Valuation Benchmark Range
🟢 Attractively Priced vs Industry Peers
Industry 97.2x
IPO 84.5x
0x (Deep Value)
131x (High Multiple)
📋 Live Subscription Status
QIB
182.65x
NII
48.94x
Retail
5.64x
Total
63.86x
🎯 Retail Allotment Probability
17.7% Odds
1 in 5.6 chance (~17.7% probability per PAN)
SEBI Rule: Under SEBI lottery allotment rules, applying for multiple lots under Retail does NOT increase your lottery odds. All valid retail applicants have identical 1-lot odds per PAN.
Updated: Sep 12, 2026 2:38 PM
💼 Issue Structure & Reservation Quota
Capital Structure
₹3,395.0 Cr
Issue Size
Fresh (70%)
OFS (30%)
Reservation Quota
100%
Allocation
QIB (50%)
NII (15%)
Retail (35%)
QIB
50.00%
Retail
35.00%
NII
15.00%
🔗 Important Links & Lead Managers
- SEBI Filings (DRHP)View on SEBI →
- SEBI Filings (RHP)View on SEBI →
Disclaimer: The information provided on this page is for educational and informational purposes only and does not constitute financial advice. IPO investments are subject to market risks. AI-generated analysis is based on publicly available data and may not be accurate. Grey Market Premium (GMP) is unofficial and highly speculative. Always consult a qualified financial advisor and read the DRHP/RHP carefully before making investment decisions.